About
Technology
Issues
FAQ
Links
Official Page
Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial
site/software ©
exaly
; All materials licenced under
CC by-SA
.